<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:34:37Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9333372" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9333372</identifier>
        <datestamp>2022-07-30</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="jah37426" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9333372</article-id>
              <article-id pub-id-type="pmcid">PMC9333372</article-id>
              <article-id pub-id-type="pmc-uid">9333372</article-id>
              <article-id pub-id-type="pmid">35730613</article-id>
              <article-id pub-id-type="pmid">35730613</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.121.024763</article-id>
              <article-id pub-id-type="publisher-id">JAH37426</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Hypertension</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Increases in Circulating and Fecal Butyrate are Associated With Reduced Blood Pressure and Hypertension: Results From the SPIRIT Trial</article-title>
                <alt-title alt-title-type="right-running-head">Short Chain Fatty Acids and Blood Pressure</alt-title>
                <alt-title alt-title-type="left-running-head">Tilves et al</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jah37426-cr-0001" contrib-type="author">
                  <name>
                    <surname>Tilves</surname>
                    <given-names>Curtis</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0281-5986</contrib-id>
                  <xref rid="jah37426-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah37426-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah37426-cr-0002" contrib-type="author">
                  <name>
                    <surname>Yeh</surname>
                    <given-names>Hsin‐Chieh</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5738-0652</contrib-id>
                  <xref rid="jah37426-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah37426-cr-0003" contrib-type="author">
                  <name>
                    <surname>Maruthur</surname>
                    <given-names>Nisa</given-names>
                  </name>
                  <degrees>MD, MHS</degrees>
                  <xref rid="jah37426-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah37426-cr-0004" contrib-type="author">
                  <name>
                    <surname>Juraschek</surname>
                    <given-names>Stephen P.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4168-2696</contrib-id>
                  <xref rid="jah37426-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah37426-cr-0005" contrib-type="author">
                  <name>
                    <surname>Miller</surname>
                    <given-names>Edgar</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0157-6258</contrib-id>
                  <xref rid="jah37426-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah37426-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah37426-cr-0006" contrib-type="author">
                  <name>
                    <surname>White</surname>
                    <given-names>Karen</given-names>
                  </name>
                  <degrees>MS, RD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2804-588X</contrib-id>
                  <xref rid="jah37426-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah37426-cr-0007" contrib-type="author">
                  <name>
                    <surname>Appel</surname>
                    <given-names>Lawrence J.</given-names>
                  </name>
                  <degrees>MD, MPH</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0673-6823</contrib-id>
                  <xref rid="jah37426-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah37426-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah37426-cr-0008" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Mueller</surname>
                    <given-names>Noel T.</given-names>
                  </name>
                  <degrees>PhD, MPH</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7412-8352</contrib-id>
                  <xref rid="jah37426-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah37426-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <address>
                    <email>nmuelle4@jhu.edu</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="jah37426-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Department of Epidemiology</named-content>
                <institution>Johns Hopkins University Bloomberg School of Public Health</institution>
                <city>Baltimore</city>
                <named-content content-type="country-part">MD</named-content>
              </aff>
              <aff id="jah37426-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Welch Center for Prevention, Epidemiology, and Clinical Research</named-content>
                <institution>Johns Hopkins University</institution>
                <city>Baltimore</city>
                <named-content content-type="country-part">MD</named-content>
              </aff>
              <aff id="jah37426-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Division of General Medicine and Primary Care</named-content>
                <institution>Beth Israel Deaconess Medical Center</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>
Correspondence to: Noel T. Mueller, 2024 E. Monument Street, Suite 2‐600, Room 2‐636, Baltimore, Maryland 21205. Email: <email>nmuelle4@jhu.edu</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>22</day>
                <month>6</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="collection">
                <day>05</day>
                <month>7</month>
                <year>2022</year>
              </pub-date>
              <volume>11</volume>
              <issue seq="220">13</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.v11.13</issue-id>
              <elocation-id>e024763</elocation-id>
              <history>
                <date date-type="received">
                  <day>12</day>
                  <month>1</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>01</day>
                  <month>4</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <!--Copyright &#x000a9; 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell-->
                <copyright-statement content-type="article-copyright">© 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JAH3-11-e024763.pdf"/>
              <abstract id="jah37426-abs-0001">
                <sec id="jah37426-sec-0001">
                  <title>Background</title>
                  <p>Short chain fatty acids (SCFAs) are microbially derived end products of dietary fiber fermentation. The SCFA butyrate reduces blood pressure (BP) in mouse models. The association of SCFAs, including butyrate, with BP in humans is unclear, due in part to predominantly cross‐sectional analyses and different biospecimens (blood versus fecal) for SCFA measurement. Longitudinal studies including both circulating and fecal SCFAs are lacking.</p>
                </sec>
                <sec id="jah37426-sec-0002">
                  <title>Methods and Results</title>
                  <p>We leveraged existing data from the SPIRIT (Survivorship Promotion In Reducing IGF‐1 Trial), which randomized 121 adult cancer survivors with overweight/obesity to a behavioral weight‐loss intervention, metformin, or self‐directed weight‐loss. Of participants with baseline serum and fecal SCFAs measured (n=111), a subset had serum (n=93) and fecal (n=89) SCFA measurements 12 months later. We used Poisson regression with robust error variance to estimate baseline associations of SCFAs with hypertension, and we assessed the percent change in SCFAs from baseline with corresponding 12‐month changes in BP using multiple linear regression. Baseline fecal butyrate was inversely associated with prevalent hypertension (standardized PR [95%CI]: 0.71 [0.54, 0.92]). A 10% increase in fecal butyrate from baseline was associated with decreased systolic BP (β [95%CI]: −0.56 [−1.01, −0.10] mm Hg), and a 10% increase in serum butyrate was associated with decreased systolic (β [95%CI]: −1.39 [−2.15, −0.63] mm Hg) and diastolic (β [95%CI]: −0.55 [−1.03, −0.08] mm Hg) BPs. Butyrate associations with systolic BP were linear and not modified by sex, race, or intervention arm.</p>
                </sec>
                <sec id="jah37426-sec-0003">
                  <title>Conclusions</title>
                  <p>Increased serum or fecal butyrate is associated with lowered BP. Butyrate may be a target for SCFA‐centered BP‐lowering interventions.</p>
                </sec>
                <sec id="jah37426-sec-0004">
                  <title>Registration</title>
                  <p>URL: <ext-link xlink:href="https://www.clinicaltrials.gov" ext-link-type="uri">https://www.clinicaltrials.gov</ext-link>; Unique identifier: NCT02431676.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd id="jah37426-kwd-0001">acetic acid</kwd>
                <kwd id="jah37426-kwd-0002">blood pressure</kwd>
                <kwd id="jah37426-kwd-0003">butyric acid</kwd>
                <kwd id="jah37426-kwd-0004">fatty acids</kwd>
                <kwd id="jah37426-kwd-0005">volatile</kwd>
                <kwd id="jah37426-kwd-0006">hypertension</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>High Blood Pressure</kwd>
                <kwd>Hypertension</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>Maryland Cigarette Restitution Fund</funding-source>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Heart, Lung, and Blood Institute
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000002</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>K01HL141589</award-id>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>
                    <institution-wrap>
                      <institution>Johns Hopkins
</institution>
                      <institution-id institution-id-type="doi">10.13039/100007880</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>5P30CA006973</award-id>
                </award-group>
                <award-group id="funding-0004">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Heart, Lung, and Blood Institute
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000050</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>T32HL007024</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="1"/>
                <table-count count="3"/>
                <page-count count="9"/>
                <word-count count="6914"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>05 July 2022</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.7 mode:remove_FC converted:05.07.2022</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <fn-group id="jah37426-ntgp-0001">
                <fn id="jah37426-note-0002">
                  <p>For Sources of Funding and Disclosures, see page 8.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="jah37426-body-0001">
            <def-list list-content="abbreviations" id="jah37426-lp-0001">
              <title>Nonstandard Abbreviations and Acronyms</title>
              <def-item>
                <term>BKMR</term>
                <def>
                  <p>Bayes kernel machine regression</p>
                </def>
              </def-item>
              <def-item>
                <term>DBP</term>
                <def>
                  <p>diastolic blood pressure</p>
                </def>
              </def-item>
              <def-item>
                <term>SBP</term>
                <def>
                  <p>systolic blood pressure</p>
                </def>
              </def-item>
              <def-item>
                <term>SCFA</term>
                <def>
                  <p>short chain fatty acid</p>
                </def>
              </def-item>
              <def-item>
                <term>SPIRIT</term>
                <def>
                  <p>Survivorship Promotion In Reducing IGF‐1 Trial</p>
                </def>
              </def-item>
            </def-list>
            <p>
              <boxed-text position="anchor" content-type="box" id="jah37426-blkfxd-0001">
                <sec id="jah37426-sec-0006">
                  <title>Clinical Perspective</title>
                  <sec id="jah37426-sec-0007">
                    <title>What Is New?</title>
                    <p>
                      <list list-type="bullet" id="jah37426-list-0001">
                        <list-item>
                          <p>Higher fecal butyrate was associated with lower prevalence of hypertension and 1‐year increases in both fecal butyrate and serum butyrate were associated with reductions in blood pressure.</p>
                        </list-item>
                        <list-item>
                          <p>One‐year changes in other short chain fatty acids were also associated with 1‐year changes in blood pressure, however associations differed by the type of biospecimen in which the fatty acid was measured.</p>
                        </list-item>
                        <list-item>
                          <p>Sex significantly modified the associations between changes in several short chain fatty acids and changes in blood pressure, but associations between butyrate and blood pressure were not modified by sex.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                  <sec id="jah37426-sec-0008">
                    <title>What Are the Clinical Implications?</title>
                    <p>
                      <list list-type="bullet" id="jah37426-list-0002">
                        <list-item>
                          <p>Butyrate may be a target for SCFA‐centered blood pressure lowering interventions.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                </sec>
              </boxed-text>
            </p>
            <sec sec-type="opening-section" id="jah37426-sec-0009">
              <p>Short chain fatty acids (SCFAs)—molecules produced by microbial fermentation of dietary fiber—are postulated to mediate associations of gut microbiota and health. Of increasing interest is the role of the SCFA butyrate in hypertension risk. Butyrate has been shown to lower blood pressure in rodent models, and these effects are thought to be through indirect effects that derive in the gut (eg, reducing inflammation through increased intestinal barrier function<xref rid="jah37426-bib-0001" ref-type="bibr"><sup>1</sup></xref> or by acting on afferent vagal nerve signaling<xref rid="jah37426-bib-0002" ref-type="bibr"><sup>2</sup></xref>) or through more direct effects in the periphery (eg, through action on G protein‐coupled receptors or by acting as a histone deacetylase inhibitor<xref rid="jah37426-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="jah37426-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="jah37426-bib-0005" ref-type="bibr"><sup>5</sup></xref>, <xref rid="jah37426-bib-0006" ref-type="bibr"><sup>6</sup></xref>).</p>
              <p>While there is a robust literature linking butyrate and blood pressure in rodents, evidence in humans has been mixed,<xref rid="jah37426-bib-0001" ref-type="bibr"><sup>1</sup></xref>, <xref rid="jah37426-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="jah37426-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="jah37426-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="jah37426-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="jah37426-bib-0011" ref-type="bibr"><sup>11</sup></xref>, <xref rid="jah37426-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="jah37426-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="jah37426-bib-0014" ref-type="bibr"><sup>14</sup></xref> possibly due to differences in the biological specimens (blood or fecal) used for SCFA measurement. This postulate is supported by results from cross‐sectional studies<xref rid="jah37426-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="jah37426-bib-0015" ref-type="bibr"><sup>15</sup></xref> which examined both circulating (blood) and excreted (fecal) SCFAs with cardiometabolic health risk factors and identified biospecimen‐specific associations. Few longitudinal analyses report associations between changes in SCFAs and blood pressure; those that do were relatively short in length (6–18 weeks) and have focused solely on SCFAs measured in blood, not fecal SCFAs.<xref rid="jah37426-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="jah37426-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="jah37426-bib-0014" ref-type="bibr"><sup>14</sup></xref> No longitudinal studies to date have simultaneously assessed how changes in both circulating (blood) and excreted (fecal) butyrate, or other SCFAs, are associated with changes in blood pressure.</p>
              <p>In this secondary analysis of a randomized trial, we examined baseline associations of serum and fecal SCFA levels with prevalent hypertension, and longitudinal associations of changes in serum and fecal SCFAs with changes in blood pressure over 1 year. Consistent with prior evidence in murine models, we hypothesized that increasing butyrate levels in humans is associated with decreases in blood pressure.</p>
            </sec>
            <sec sec-type="methods" id="jah37426-sec-0010">
              <title>Methods</title>
              <sec sec-type="data-availability" id="jah37426-sec-0011">
                <title>Data Availability Statement</title>
                <p>Data described in the manuscript, codebook, and analytic code will be made available upon reasonable request.</p>
              </sec>
              <sec id="jah37426-sec-0012">
                <title>Study Population</title>
                <p>The SPIRIT (Survivorship Promotion In Reducing IGF‐1 Trial) was a 3 arm randomized trial with a parallel design in adult cancer survivors with a body mass index (BMI) corresponding to overweight or obese categories.<xref rid="jah37426-bib-0016" ref-type="bibr"><sup>16</sup></xref> The primary outcome was insulin‐like growth factor‐1. The full protocol for SPIRIT can be found at ClinicalTrial.gov (identifier: NCT02431676). We recruited and enrolled participants at the Johns Hopkins ProHealth clinical research unit (Baltimore, MD) between August 2015 and December 2016. Relevant inclusion criteria for SPIRIT were: age ≥18 years, a previous solid tumor diagnosis and treatment‐free survival of at least 1 year and a BMI ≥25 kg/m<sup>2</sup> with a weight ≤400 pounds. Relevant exclusion criteria were: current pregnancy or breastfeeding; antidiabetic medication use, fasting glucose ≥200 mg/dL, or fasting glucose ≥126 mg/dL and hemoglobin A1c≥7%; chemotherapy, radiation treatment, or metformin use within past 3 months; an estimated glomerular filtration rate &lt;45; hepatic dysfunction, defined as Aspartate aminotransferase (AST)/Alanine transaminase (ALT) ≥2 times the upper limit of normal or reported liver disease; alcohol consumption &gt;14 drinks per week; and prior or planned bariatric surgery.</p>
                <p>Of the 121 participants included in SPIRIT, 111 participants had data for both serum and fecal SCFAs, blood pressure, and relevant covariates at baseline. A subset of these participants also had complete baseline and 12‐month post‐randomization serum (n=93) and fecal (n=89) SCFA measures. The Institutional Review Board at Johns Hopkins University approved the study protocol. All participants provided written informed consent.</p>
              </sec>
              <sec id="jah37426-sec-0013">
                <title>Treatment Groups</title>
                <p>We randomized participants 1:1:1 to (1) coach‐directed weight loss, (2) metformin treatment arm, or (3) self‐directed weight loss, with stratification by race and BMI with variable block sizes. Participants in the coach‐directed arm received a remotely delivered lifestyle intervention consisting of increased physical activity, reduced calorie intake, and guidance to eat the Dietary Approaches to Stopping Hypertension (DASH) diet; the weight‐loss goal for this arm was 5% weight loss by the 6‐month timepoint, with maintenance of weight loss through the remainder of the study. The metformin arm received metformin up to 2000 mg per day, as tolerated by participants. The self‐directed weight loss control participants received printed materials on weight loss at baseline.</p>
              </sec>
              <sec id="jah37426-sec-0014">
                <title>Collection and Storage of Biospecimens</title>
                <p>We collected stool and fasting serum at baseline, 6 months, and 12 months. We stored aliquots of serum at −80 °C. At each study visit, we provided participants with an OMNIgene kit (DNA Genotek Inc., Ontario, Canada) to self‐collect their stool at home. We instructed participants to refrigerate the stool samples at home and return them to the clinical center within 1 day, where the stool samples were stored at −80 °C.</p>
              </sec>
              <sec id="jah37426-sec-0015">
                <title>Primary Exposure: Fecal and Serum Short Chain Fatty Acids</title>
                <p>Fecal SCFAs were measured by Microbiome Insights using gas chromatography following a previously published protocol.<xref rid="jah37426-bib-0017" ref-type="bibr"><sup>17</sup></xref> In brief, fecal samples were suspended in MilliQ‐grade water, homogenized (MP Bio FastPrep), and acidified to a pH of 2.0 using 5 M HCl. These suspensions were centrifuged at 14 257<italic toggle="yes">g</italic>, whereafter the supernatants were extracted and spiked with 2‐Ethylbutyric acid (to a 1 mmol/L concentration) before being stored in 2‐mL GC vials with glass inserts. SCFAs were then measured by gas chromatography (Thermo Trace 1310) coupled with flame ionization detection (Thermo). Results were reported in mmol SCFA/kg feces. The SCFAs acetate, propionate, butyrate, isobutyrate, valerate, isovalerate, and hexanoate were measured in fecal samples; however, a large proportion of participants showed measures of 0 mmol/kg at baseline for fecal SCFAs isobutyrate, valerate, and hexanoate (58.1%, 30.1%, and 75.3% of participants, respectively). Because our primary analysis was focused on percent change in SCFAs from baseline and the co‐modeling of SCFAs within a biospecimen, we excluded these 3 fecal SCFAs from both cross‐sectional and longitudinal analyses to maintain a sufficient sample size and consistency between analyses. The sum of acetate, propionate, butyrate, and isovalerate were used to calculate a “total” fecal SCFA level. The lower limit of quantitation was 30.1 µmol/L for acetate, 15.2 µmol/L for propionate, 11.2 µmol/L for butyrate, and 7.7 µmol/L for isovalerate. The inter‐assay coefficient of variation was ≈10% for all fecal SCFAs.</p>
                <p>Serum SCFAs were measured by Metabolon using liquid chromatography as previously described.<xref rid="jah37426-bib-0018" ref-type="bibr"><sup>18</sup></xref> In brief, fasting serum samples were spiked with a solution containing stable labeled internal standards for each SCFA. Following protein precipitation and centrifugation, an aliquot of the supernatant was derivatized and analyzed by liquid chromatography mass spectrometry (Agilent 1290/AB Sciex 5500). The peak area for each SCFA was measured against its corresponding internal standard peak. SCFAs were quantified using a weighted least squares regression analysis based on calibration standards, and SCFA measures outside the limits of quantitation were further extrapolated beyond these limits. Results are reported in ng SCFA/mL serum. The SCFAs acetate, propionate, butyrate, isobutyrate, valerate, isovalerate, and hexanoate were measured in serum samples, and the sum of all SCFAs was used to calculate a “total” serum SCFA level. The lower limit of quantitation was 25 ng/mL (butyrate, isobutyrate, methylbutyrate, valerate, and isovalerate), 50 ng/mL (hexanoate), 100 ng/mL (propionate), and 1000 ng/mL (acetate). The coefficients of variation were &lt;7% for serum SCFAs.</p>
              </sec>
              <sec id="jah37426-sec-0016">
                <title>Blood Pressure and Hypertension</title>
                <p>We measured systolic (SBP) and diastolic (DBP) blood pressure using an automated oscillometric device (Omron HEM 907XL). Participants rested for 5 minutes in a seated position with feet flat on the floor, their right arm positioned with the elbow and forearm resting comfortably on a table, and their palm turned upwards; the left arm was used in participants with a history of breast cancer with lymph node dissection in the right arm. A trained and certified data collector measured the blood pressure from the positioned arm of participants using an appropriately sized cuff. Three consecutive measures were obtained (with 30 seconds between measurements), and an average blood pressure was reported. We defined hypertension [yes/no] using the AHA/ACC blood pressure cutoffs for stage 1 or 2 hypertension (SBP ≥130 mm Hg or DBP ≥80 mm Hg),<xref rid="jah37426-bib-0019" ref-type="bibr"><sup>19</sup></xref> or use of an antihypertensive medication regardless of measured blood pressure.</p>
              </sec>
              <sec id="jah37426-sec-0017">
                <title>Other Covariates</title>
                <p>Participants self‐reported age, sex, and race. We collected data on antihypertensive medication use at each study visit and we dichotomized antihypertensive medication use [yes/no]. We measured weight at each visit using a digital scale without shoes. We measured height was measured at the study entry, and calculated BMI using height and weight (kg/m<sup>2</sup>). Participants filled out a fruit and vegetable screening questionnaire (National Cancer Institute Eating at America’s Table Study Quick Food Scan) at each study visit. We estimated fiber intake (in grams) using a regression model based on self‐reported fruit/vegetable/legume intake, age, and sex.</p>
              </sec>
              <sec id="jah37426-sec-0018">
                <title>Statistical Analysis</title>
                <p>In cross‐sectional analyses, to determine the presence of nonlinear and nonadditive associations of serum or fecal SCFAs with hypertension, we used a Bayesian kernel machine regression (BKMR) approach. BKMR applies a kernel machine regression model to estimate a multivariable exposure‐response function.<xref rid="jah37426-bib-0020" ref-type="bibr"><sup>20</sup></xref> It then allows for graphical visualizations of the estimated exposure‐response function by setting some exposures to specific quantile values and examining the associations of the remaining exposures to the outcome. For dichotomous outcomes, BKMR uses probit regression. We standardized SCFAs prior to model entry, and models were run separately for inclusion of all serum SCFAs or for all fecal SCFAs. We adjusted all models for age (continuous), BMI (continuous), sex (male or female), and fiber intake (continuous). We fit BKMR models using 100 000 iterations and without variable selection. Using BKMR, we visualized the exposure‐response functions in 3 different ways: (1) the overall joint effect of SCFA exposures, in which we compared the exposure‐response function when all SCFAs are at a particular quantile to when they are all at their 50th percentile levels; (2) the univariate effect of each SCFA, in which we compared the association of one SCFA with an outcome while holding the remaining SCFAs at their median values; and (3) potential 2‐way interaction effects between SCFAs, in which we plotted the effect of one SCFA at fixed levels (10th, 50th, and 90th percentiles) of a second, while holding the remaining SCFAs at their 50th percentile values.</p>
                <p>To corroborate the baseline BKMR findings and to provide statistical test assessments, we used Poisson regression models with robust error variances to estimate associations of a 1 SD increase in total or individual SCFAs with the prevalence ratio of hypertension at baseline. We adjusted all models for age, sex, BMI, and fiber intake, and we ran models separately for serum and fecal SCFAs.</p>
                <p>For our 12‐month longitudinal change analyses, we included only participants with complete change data and non‐zero baseline SCFA values, resulting in 93 participants with changes in serum SCFAs and 89 participants with changes in fecal SCFAs. We presented 12‐month changes in blood pressure, weight, and fiber as mean change (95% CI) and in SCFAs as median change (95% CI). To examine potential non‐linear relations, we used restricted cubic splines with 3 knots for the percent changes in each of the SCFAs. Nonlinearity was assessed graphically and using an F test for the nonlinear term. We used linear regression models to assess the effects of a percent change in serum or fecal SCFAs from baseline with corresponding 12‐month absolute changes in blood pressure. We adjusted models for baseline age, sex, baseline BMI, baseline blood pressure (SBP or DBP), intervention group, baseline antihypertensive medication use, baseline fiber intake, change in weight, and percent change in other serum or fecal SCFAs. We used heteroscedasticity‐consistent White standard errors if heteroscedasticity was present.</p>
                <p>We examined effect measure modification by sex, race, or treatment group in separate models using interaction terms for all variables as suggested in Buckley et al.<xref rid="jah37426-bib-0021" ref-type="bibr"><sup>21</sup></xref> As we identified sex modification for several SCFAs, we report main effects (with sex interaction terms included for remaining variables) for our primary longitudinal results; stratified results for sex, race, and treatment group are reported in the supplemental material.</p>
                <p>We performed BKMR models using the <italic toggle="yes">bkmr</italic> package<xref rid="jah37426-bib-0022" ref-type="bibr"><sup>22</sup></xref> and restricted cubic spline models with the <italic toggle="yes">rms</italic> package<xref rid="jah37426-bib-0023" ref-type="bibr"><sup>23</sup></xref> in R version 4.0.2; we performed all remaining analyses using SAS version 9.4 (SAS Institute, Inc., Cary, North Carolina). We based statistical significance on an α&lt;0.05.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="jah37426-sec-0019">
              <title>Results</title>
              <sec id="jah37426-sec-0020">
                <title>Baseline Characteristics and Cross‐Sectional Associations of SCFAs With Hypertension</title>
                <p>Nearly 68% of participants had hypertension at baseline (Table <xref rid="jah37426-tbl-0001" ref-type="table">1</xref>). Of those who were classified as having hypertension, a majority were taking an antihypertensive medication. A majority of those taking an antihypertensive medication were on a diuretic, beta‐blocker, ACE inhibitor, Angiotensin II receptor blocker, or calcium channel blocker (Table <xref rid="jah37426-sup-0001" ref-type="supplementary-material">S1</xref>). Participants were several years from a past cancer treatment (median 6 years), with most participants having a history of breast cancer.</p>
                <table-wrap position="float" id="jah37426-tbl-0001" content-type="Table">
                  <label>Table 1</label>
                  <caption>
                    <p>Baseline Characteristics of Sample (n=111)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Variable</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Mean (SD), Median (interquartile range), or n (%)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age, y</td>
                        <td align="left" rowspan="1" colspan="1">60.2 (8.9)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Female sex, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">87 (78.4%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Black or African American, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">52 (46.9%)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="2" rowspan="1">Treatment group assignment, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Self‐directed</td>
                        <td align="left" rowspan="1" colspan="1">38 (34.2%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Coach‐directed</td>
                        <td align="left" rowspan="1" colspan="1">34 (30.6%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Metformin</td>
                        <td align="left" rowspan="1" colspan="1">39 (35.1%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Fiber, g/d</td>
                        <td align="left" rowspan="1" colspan="1">11.1 (4.8)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Weight, kg</td>
                        <td align="left" rowspan="1" colspan="1">95.5 (16.9)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">34.9 (5.4)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="2" rowspan="1">Type of cancer, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Breast</td>
                        <td align="left" rowspan="1" colspan="1">62 (55.9%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Colorectal</td>
                        <td align="left" rowspan="1" colspan="1">11 (9.9%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prostate</td>
                        <td align="left" rowspan="1" colspan="1">10 (9.0%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Thyroid</td>
                        <td align="left" rowspan="1" colspan="1">9 (8.1%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Time since last cancer treatment, y<xref rid="jah37426-note-0004" ref-type="table-fn">*</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">6.0 (3.0, 13.0)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="2" rowspan="1">Blood pressure</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">SBP, mm Hg</td>
                        <td align="left" rowspan="1" colspan="1">118.5 (15.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">DBP, mm Hg</td>
                        <td align="left" rowspan="1" colspan="1">69.8 (9.5)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Antihypertensive Medication, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">67 (60.4%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">75 (67.6%)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="2" rowspan="1">Short chain fatty acids</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total serum SCFAs, ng/mL</td>
                        <td align="left" rowspan="1" colspan="1">2359.2 (1923.8, 3076.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Serum acetate, ng/mL</td>
                        <td align="left" rowspan="1" colspan="1">1270.0 (958.0, 2150.0)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Serum propionate, ng/mL</td>
                        <td align="left" rowspan="1" colspan="1">149.0 (110.0, 204.0)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Serum butyrate, ng/mL</td>
                        <td align="left" rowspan="1" colspan="1">62.7 (51.7, 79.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Serum isobutyrate, ng/mL</td>
                        <td align="left" rowspan="1" colspan="1">530.0 (426.0, 650.0)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Serum methylbutyrate, ng/mL</td>
                        <td align="left" rowspan="1" colspan="1">82.1 (62.7, 110.0)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Serum isovalerate, ng/mL</td>
                        <td align="left" rowspan="1" colspan="1">68.1 (49.5, 99.2)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Serum valerate, ng/mL</td>
                        <td align="left" rowspan="1" colspan="1">19.5 (15.7, 24.4)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Serum hexanoate, ng/mL</td>
                        <td align="left" rowspan="1" colspan="1">66.9 (59.1, 76.3)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total fecal SCFAs, mmol/kg</td>
                        <td align="left" rowspan="1" colspan="1">14.0 (11.2, 18.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Fecal acetate, mmol/kg</td>
                        <td align="left" rowspan="1" colspan="1">7.6 (5.7, 10.0)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Fecal propionate, mmol/kg</td>
                        <td align="left" rowspan="1" colspan="1">4.2 (3.3, 5.3)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Fecal butyrate, mmol/kg</td>
                        <td align="left" rowspan="1" colspan="1">1.7 (1.2, 2.3)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Fecal isovalerate, mmol/kg</td>
                        <td align="left" rowspan="1" colspan="1">0.4 (0.3, 0.6)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah37426-ntgp-0002">
                    <fn id="jah37426-note-0003">
                      <p>BMI indicates body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; and SCFA, short chain fatty acid.</p>
                    </fn>
                    <fn id="jah37426-note-0004">
                      <label>*</label>
                      <p>n=107.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <p>We used BKMR (see Methods) to examine the mixture effects of serum and fecal SCFAs on prevalent hypertension. BKMR plots indicated an inverse association between the mixture of fecal SCFAs with prevalent hypertension and a null association for the mixture of serum SCFAs and hypertension (Figure <xref rid="jah37426-sup-0001" ref-type="supplementary-material">S1</xref>). Univariable associations of individual SCFAs (in both serum and stool) with hypertension appeared to be mostly linear (Figure <xref rid="jah37426-sup-0001" ref-type="supplementary-material">S2</xref>). Among the SCFAs examined in BKMR, serum propionate and serum valerate showed modest positive associations with hypertension, while fecal butyrate showed an inverse association with hypertension. BKMR visualizations of bivariable interaction plots did not indicate strong interaction effects between SCFAs on hypertension (Figures <xref rid="jah37426-sup-0001" ref-type="supplementary-material">S3 and S4</xref>).</p>
                <p>We next corroborated BKMR findings using traditional linear regression models (Table <xref rid="jah37426-tbl-0002" ref-type="table">2</xref>). After adjustment for covariates, we found that among serum SCFAs, valerate trended toward a positive association (albeit not statistically significant) with hypertension while other serum SCFAs were null. Among fecal SCFAs, butyrate was significantly inversely associated with hypertension, and the association of total fecal SCFAs with hypertension trended inverse but was not statistically significant.</p>
                <table-wrap position="float" id="jah37426-tbl-0002" content-type="Table">
                  <label>Table 2</label>
                  <caption>
                    <p>Baseline Associations of a 1‐SD Increment in SCFAs With Hypertension Status (n=111)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Serum SCFAs</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Fecal SCFAs</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">SCFA predictors</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">SCFA SD (ng/mL)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Hypertension prevalence ratio (95% CI)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">SCFA SD (mmol/kg)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Hypertension prevalence ratio (95% CI)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Total SCFAs</td>
                        <td align="left" rowspan="1" colspan="1">969.1</td>
                        <td align="left" rowspan="1" colspan="1">0.99 (0.88, 1.11)</td>
                        <td align="left" rowspan="1" colspan="1">6.1</td>
                        <td align="left" rowspan="1" colspan="1">0.87 (0.75, 1.01)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Acetate</td>
                        <td align="char" rowspan="1" colspan="1">885.3</td>
                        <td align="left" rowspan="1" colspan="1">1.02 (0.87, 1.19)</td>
                        <td align="left" rowspan="1" colspan="1">3.6</td>
                        <td align="left" rowspan="1" colspan="1">1.10 (0.87, 1.38)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Propionate</td>
                        <td align="left" rowspan="1" colspan="1">71.3</td>
                        <td align="left" rowspan="1" colspan="1">1.06 (0.88, 1.29)</td>
                        <td align="left" rowspan="1" colspan="1">1.9</td>
                        <td align="left" rowspan="1" colspan="1">1.02 (0.84, 1.24)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Butyrate</td>
                        <td align="left" rowspan="1" colspan="1">34.1</td>
                        <td align="left" rowspan="1" colspan="1">0.90 (0.72, 1.12)</td>
                        <td align="left" rowspan="1" colspan="1">1.0</td>
                        <td align="left" rowspan="1" colspan="1">0.71 (0.54, 0.92)<xref rid="jah37426-note-0006" ref-type="table-fn">*</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Isobutyrate</td>
                        <td align="left" rowspan="1" colspan="1">158.0</td>
                        <td align="left" rowspan="1" colspan="1">1.02 (0.85, 1.22)</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Methylbutyrate</td>
                        <td align="left" rowspan="1" colspan="1">34.3</td>
                        <td align="left" rowspan="1" colspan="1">1.07 (0.93, 1.24)</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Isovalerate</td>
                        <td align="left" rowspan="1" colspan="1">36.3</td>
                        <td align="left" rowspan="1" colspan="1">0.94 (0.77, 1.15)</td>
                        <td align="left" rowspan="1" colspan="1">0.2</td>
                        <td align="left" rowspan="1" colspan="1">1.04 (0.89, 1.22)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Valerate</td>
                        <td align="left" rowspan="1" colspan="1">8.3</td>
                        <td align="left" rowspan="1" colspan="1">1.15 (0.98, 1.36)</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hexanoate</td>
                        <td align="left" rowspan="1" colspan="1">15.3</td>
                        <td align="left" rowspan="1" colspan="1">0.91 (0.78, 1.07)</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah37426-ntgp-0003">
                    <fn id="jah37426-note-0005">
                      <p>Adjusted covariates: age, sex, BMI, and fiber intake. Models including individual SCFAs additionally adjust for remaining specimen SCFAs. BMI indicates body mass index; and SCFA, short chain fatty acid.</p>
                    </fn>
                    <fn id="jah37426-note-0006">
                      <label>*</label>
                      <p>is statistically significant at <italic toggle="yes">P</italic>&lt;0.05.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
              </sec>
              <sec id="jah37426-sec-0021">
                <title>Longitudinal Changes in SCFAs and BP</title>
                <p>We report 12‐month changes in SCFAs and blood pressure, along with changes in body weight and dietary fiber, overall and by treatment group (Table <xref rid="jah37426-sup-0001" ref-type="supplementary-material">S2</xref>). We found no treatment group differences in changes in blood pressure, fiber, or SCFAs. In Table <xref rid="jah37426-tbl-0003" ref-type="table">3</xref> we demonstrate how a 10% increase in SCFAs is associated with change in SBP and DBP over 12 months. Notably, increases in serum acetate were positively associated with increases in SBP and DBP over 12 months. In contrast, increases in serum and fecal butyrate were significantly associated with decreases in SBP over 12 months, and an increase in serum butyrate was also associated with a decrease in DBP over 12 months. We did not find evidence for nonlinearity of associations using restricted cubic spline models (all <italic toggle="yes">P</italic> values &gt;0.05).</p>
                <table-wrap position="float" id="jah37426-tbl-0003" content-type="Table">
                  <label>Table 3</label>
                  <caption>
                    <p>Main Effect (β [95% CI]) of a 10% Increase in 12‐Month SCFA on 12‐Month Change in Blood Pressure</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Predictor</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">12‐month Δ SBP (mm Hg)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">12‐month Δ DBP (mm Hg)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">%Δ Serum total SCFAs</td>
                        <td align="left" rowspan="1" colspan="1">0.57 (0.01, 1.12)<xref rid="jah37426-note-0009" ref-type="table-fn"><sup>†</sup></xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.19 (−0.12, 0.51)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">%Δ Serum acetate</td>
                        <td align="left" rowspan="1" colspan="1">0.62 (0.32, 0.91)<xref rid="jah37426-note-0009" ref-type="table-fn"><sup>†</sup></xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.26 (0.08, 0.45)<xref rid="jah37426-note-0009" ref-type="table-fn"><sup>†</sup></xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">%Δ Serum propionate</td>
                        <td align="left" rowspan="1" colspan="1">−0.04 (−1.11, 1.04)</td>
                        <td align="left" rowspan="1" colspan="1">−0.05 (−0.57, 0.46)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">%Δ Serum butyrate</td>
                        <td align="left" rowspan="1" colspan="1">−1.39 (−2.15, −0.63)<xref rid="jah37426-note-0009" ref-type="table-fn"><sup>†</sup></xref>
</td>
                        <td align="left" rowspan="1" colspan="1">−0.55 (−1.03, −0.08)<xref rid="jah37426-note-0009" ref-type="table-fn"><sup>†</sup></xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">%Δ Serum isobutyrate</td>
                        <td align="left" rowspan="1" colspan="1">0.76 (−0.73, 2.25)</td>
                        <td align="left" rowspan="1" colspan="1">0.59 (−0.33, 1.51)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">%Δ Serum methylbutyrate</td>
                        <td align="left" rowspan="1" colspan="1">−0.91 (−1.86, 0.03)</td>
                        <td align="left" rowspan="1" colspan="1">−0.06 (−0.68, 0.56)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">%Δ Serum isovalerate</td>
                        <td align="left" rowspan="1" colspan="1">−0.30 (−0.86, 0.26)</td>
                        <td align="left" rowspan="1" colspan="1">−0.20 (−0.54, 0.14)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">%Δ Serum valerate</td>
                        <td align="left" rowspan="1" colspan="1">0.59 (−0.97, 2.14)</td>
                        <td align="left" rowspan="1" colspan="1">−0.17 (−1.12, 0.77)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">%Δ Serum hexanoate</td>
                        <td align="left" rowspan="1" colspan="1">−0.62 (−2.33, 1.10)</td>
                        <td align="left" rowspan="1" colspan="1">0.23 (−0.95, 1.40)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">%Δ Fecal total SCFAs<xref rid="jah37426-note-0008" ref-type="table-fn">*</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">−0.03 (−0.22, 0.15)</td>
                        <td align="left" rowspan="1" colspan="1">0.07 (−0.07, 0.20)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">%Δ Fecal acetate<xref rid="jah37426-note-0008" ref-type="table-fn">*</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.22 (−0.32, 0.75)</td>
                        <td align="left" rowspan="1" colspan="1">−0.00 (−0.31, 0.30)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">%Δ Fecal propionate<xref rid="jah37426-note-0008" ref-type="table-fn">*</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">−0.00 (−0.53, 0.52)</td>
                        <td align="left" rowspan="1" colspan="1">0.12 (−0.16, 0.41)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">%Δ Fecal butyrate<xref rid="jah37426-note-0008" ref-type="table-fn">*</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">−0.56 (−1.01, −0.10)<xref rid="jah37426-note-0009" ref-type="table-fn"><sup>†</sup></xref>
</td>
                        <td align="left" rowspan="1" colspan="1">−0.16 (−0.43, 0.11)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">%Δ Fecal isovalerate<xref rid="jah37426-note-0008" ref-type="table-fn">*</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.12 (−0.24, 0.47)</td>
                        <td align="left" rowspan="1" colspan="1">0.03 (−0.21, 0.28)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah37426-ntgp-0004">
                    <fn id="jah37426-note-0007">
                      <p>Models adjusted for treatment assignment, baseline age, sex, baseline BMI, baseline blood pressure (SBP or DBP), baseline (yes/no) antihypertensive medication use, baseline fiber intake, change in weight, and sex interaction terms. Models with individual SCFAs also adjust for the percent change in remaining specimen SCFAs. BMI indicates body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; and SCFA, short chain fatty acid.</p>
                    </fn>
                    <fn id="jah37426-note-0008">
                      <label>*</label>
                      <p>n=89 for fecal SCFA.</p>
                    </fn>
                    <fn id="jah37426-note-0009">
                      <label>
                        <sup>†</sup>
                      </label>
                      <p>indicates statistical significance at <italic toggle="yes">P</italic>&lt;0.05.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
              </sec>
              <sec id="jah37426-sec-0022">
                <title>Sex, Race, and Intervention Arm Interactions</title>
                <p>Associations of several SCFAs, particularly those measured in serum, differed by sex (<xref rid="jah37426-fig-0001" ref-type="fig">Figure</xref> and Table <xref rid="jah37426-sup-0001" ref-type="supplementary-material">S3</xref>). Of note, in males there was an inverse association between change in serum propionate and SBP and positive association between change in serum isobutyrate and SBP. Moreover, in males there was a positive association between change in fecal propionate and SBP. Of note, the association of serum butyrate and fecal butyrate with SBP were consistent by sex.</p>
                <fig position="float" fig-type="Figure" id="jah37426-fig-0001">
                  <label>Figure  </label>
                  <caption>
                    <title>Forest plots of sex‐stratified β (95% CI) for effect of a 10% increase in SCFAs from baseline on change in SBP.</title>
                    <p>Coefficients obtained from sex‐stratified multivariable regression models adjusting for baseline age, baseline BMI, baseline blood pressure (SBP or DBP), intervention group, baseline antihypertensive medication use, baseline fiber intake, change in weight, and percent change in other serum or fecal SCFAs. BMI indicates body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; and SCFA, short chain fatty acid. *SCFAs significantly modified by sex.</p>
                  </caption>
                  <graphic xlink:href="JAH3-11-e024763-g001" position="anchor" id="jats-graphic-1"/>
                </fig>
                <p>Some race interactions were identified. Notably, serum hexanoate and fecal butyrate were inversely associated with change in DBP in Black participants only; and associations of percent change in total fecal SCFAs with blood pressure trended towards an inverse association with SBP or DBP in Black participants only (Table <xref rid="jah37426-sup-0001" ref-type="supplementary-material">S4</xref>). We also report evidence for treatment group‐specific effects of several serum SCFAs with blood pressure (Tables <xref rid="jah37426-sup-0001" ref-type="supplementary-material">S5 and S6</xref>). Association of serum and fecal butyrate with changes in systolic BP, however, were not modified by treatment group.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="jah37426-sec-0023">
              <title>Discussion</title>
              <p>In a racially diverse population of adult cancer survivors with overweight and obesity, we found that higher levels of fecal butyrate were inversely associated with prevalent hypertension and that increases in serum or fecal butyrate over 1 year of follow up were associated with lower blood pressure. We also identified effect modification by sex and by intervention arm for several SCFAs, but notably not for serum or fecal butyrate. Based on these data, we conclude that that butyrate may be a potential target for SCFA‐centered blood pressure lowering interventions, however the clinical significance of changes in butyrate still need to be determined.</p>
              <p>Previous cross‐sectional human studies have generally indicated that circulating butyrate (ie, measured in blood) is inversely associated,<xref rid="jah37426-bib-0001" ref-type="bibr"><sup>1</sup></xref>, <xref rid="jah37426-bib-0008" ref-type="bibr"><sup>8</sup></xref> and fecal butyrate is positively associated,<xref rid="jah37426-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="jah37426-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="jah37426-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="jah37426-bib-0012" ref-type="bibr"><sup>12</sup></xref> with blood pressure and hypertension. In contrast, dietary intervention studies have reported no associations of changes in circulating butyrate with changes in blood pressure.<xref rid="jah37426-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="jah37426-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="jah37426-bib-0014" ref-type="bibr"><sup>14</sup></xref> Divergent results across studies may be due to differences in study exclusion criteria related to blood pressure or BMI categories. Additionally, some prior studies did not account for BMI in their modeling or study design.<xref rid="jah37426-bib-0001" ref-type="bibr"><sup>1</sup></xref>, <xref rid="jah37426-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="jah37426-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="jah37426-bib-0010" ref-type="bibr"><sup>10</sup></xref> Individuals with obesity have higher levels of fecal SCFAs compared with lean individuals,<xref rid="jah37426-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="jah37426-bib-0025" ref-type="bibr"><sup>25</sup></xref> which may reflect an increased ability of the microbiome to harvest energy.<xref rid="jah37426-bib-0026" ref-type="bibr"><sup>26</sup></xref> However, studies have also reported that SCFA supplementation protects against a high‐fat diet‐induced obesity in mice<xref rid="jah37426-bib-0027" ref-type="bibr"><sup>27</sup></xref>, <xref rid="jah37426-bib-0028" ref-type="bibr"><sup>28</sup></xref> and against weight gain in humans with overweight status.<xref rid="jah37426-bib-0029" ref-type="bibr"><sup>29</sup></xref> Our study population comprised individuals with overweight or obesity by design, and we adjusted for BMI and weight change in our models; thus, we may be better able to disentangle some of the confounding or mediating effects of body habitus on SCFA‐blood pressure associations. Our study population also had relatively well‐controlled blood pressure; it is possible that our findings may be even more pronounced in populations with poorly controlled blood pressure. We also cannot rule out the possibility that differences across studies arose from differences in mass spectrometry measurement techniques; residual or unmeasured confounding by factors such as dietary intake; or by differences in the composition of our study population (compared to others) that are not related to BMI or blood pressure.</p>
              <p>There is biologic plausibility to the observed inverse association between butyrate and blood pressure in our study. In murine models, supplemental oral butyrate reduces blood pressure.<xref rid="jah37426-bib-0001" ref-type="bibr"><sup>1</sup></xref>, <xref rid="jah37426-bib-0011" ref-type="bibr"><sup>11</sup></xref>, <xref rid="jah37426-bib-0030" ref-type="bibr"><sup>30</sup></xref>, <xref rid="jah37426-bib-0031" ref-type="bibr"><sup>31</sup></xref> In addition, in human studies, individuals with hypertension have been reported to have lower levels of butyrate‐producing bacteria.<xref rid="jah37426-bib-0001" ref-type="bibr"><sup>1</sup></xref>, <xref rid="jah37426-bib-0008" ref-type="bibr"><sup>8</sup></xref> Butyrate is the primary energy source for colonocytes and promotes intestinal barrier integrity,<xref rid="jah37426-bib-0032" ref-type="bibr"><sup>32</sup></xref> which can prevent the translocation of pro‐inflammatory products. Butyrate also exhibits anti‐inflammatory effects through histone deacetylase inhibition and cytokine inhibition.<xref rid="jah37426-bib-0012" ref-type="bibr"><sup>12</sup></xref> Further, butyrate may lower blood pressure through afferent vagal nerve signaling.<xref rid="jah37426-bib-0002" ref-type="bibr"><sup>2</sup></xref> Regardless of the exact mechanism(s) of action underlying butyrate’s effects on blood pressure, our findings support increasing butyrate as a potential intervention to lower blood pressure.</p>
              <p>We found that the association of several SCFAs with blood pressure differed by sex, suggesting that the effects of the microbes and their metabolites may differ by sex. There is a growing literature base that has documented sex differences in the microbiome<xref rid="jah37426-bib-0033" ref-type="bibr"><sup>33</sup></xref>, <xref rid="jah37426-bib-0034" ref-type="bibr"><sup>34</sup></xref> and sex differences in hypertension.<xref rid="jah37426-bib-0035" ref-type="bibr"><sup>35</sup></xref>, <xref rid="jah37426-bib-0036" ref-type="bibr"><sup>36</sup></xref> Mechanisms involving diet and the immune system may underly sex differences in both the microbiome and blood pressure. Diet has been shown to differentially impact the microbiome of males compared with females,<xref rid="jah37426-bib-0037" ref-type="bibr"><sup>37</sup></xref> and there are immune response differences between males and females which may be further impacted by microbiome differences.<xref rid="jah37426-bib-0038" ref-type="bibr"><sup>38</sup></xref> Increased sodium intake can lead to reductions in salt‐sensitive <italic toggle="yes">Lactobacillus spp</italic>. and increases in T helper 17 cells and blood pressure,<xref rid="jah37426-bib-0039" ref-type="bibr"><sup>39</sup></xref> and a recent randomized trial also identified sex‐specific changes in circulating SCFAs in response to sodium reduction.<xref rid="jah37426-bib-0013" ref-type="bibr"><sup>13</sup></xref> Future work is needed to replicate our findings of sex differences in associations of SCFAs with blood pressure.</p>
              <p>We also report differences in associations of several SCFAs with blood pressure by intervention group. This suggests that the way in which some SCFAs are changed may influence their association with blood pressure. Our group previously reported that individuals in the SPIRIT metformin intervention arm showed increased acetate‐producing pathways in their gut microbiome.<xref rid="jah37426-bib-0018" ref-type="bibr"><sup>18</sup></xref> Interestingly, the metformin intervention group in our analysis showed a (non‐significant) greater reduction in daily fiber intake compared with the other intervention arms. Thus, the differential impacts of interventions on lifestyle characteristics, SCFA precursors, and SCFA‐generating capacity may counteract each other; the mechanisms underlying these differences require replication and further investigation.</p>
              <p>Our study has limitations. First, our measures of serum and fecal SCFAs were derived using different methodologies (liquid versus gas chromatography, respectively). While these assessments did allow for direct quantitation of SCFAs within a specimen, potential differences in measurement error preclude us from directly comparing SCFAs across specimen types. Second, our fecal analyses were limited to the 4 most abundant SCFAs in our sample, though the other SCFAs could also play a role in the etiology of hypertension. Third, we cannot rule out the possibility that collection or storage of biospecimens influenced SCFA measurements, or the possibility of reverse causation (eg, individuals undergo medication or lifestyle changes following a high blood pressure diagnosis and subsequently alter their microbiome/SCFA production). Fourth, our analytic sample size is relatively small for our sex and treatment group stratified results, which may lead to false positive or false negative subgroup findings. Fifth, our measurements of diet did not allow us to assess the effects of specific food groups, sodium, or total energy intake. Sixth, our study population consists of adult cancer survivors with overweight and obesity, and thus our findings may not be generalizable to younger individuals, those with normal weights, or those without a history of cancer. While treatments for cancer can affect the microbiome, the median time since last cancer treatment for participants in this analysis was ≈6 years, with only 3 individuals reporting a last treatment under 1 year prior to enrollment. Finally, it is possible that the relationship between SCFAs, including butyrate, and blood pressure may be underestimated in our study because of the high proportion of participants on antihypertensive medications.</p>
              <p>Our study also has several strengths. Our study population was diverse and included individuals of both sexes and of both Black and White race identification. Furthermore, there were high rates of retention and data collection at 1 year of follow‐up. With longitudinal follow‐up of a year, this analysis is the longest longitudinal assessment of both serum and fecal SCFAs with blood pressure in humans. To our knowledge, this is the first study to also assess the effects of changes in SCFAs independent of changes in other specimen SCFAs. Additionally, this is the first study to our knowledge to apply BKMR methods to SCFA data, allowing for the co‐modeling of SCFAs within a specimen.</p>
              <sec id="jah37426-sec-0024">
                <title>Perspectives</title>
                <p>In our longitudinal study, in which we model the independent effects of changes in serum or fecal SCFAs, we identified butyrate as a potential target for SCFA‐centered blood pressure lowering interventions. Future analyses investigating the mechanisms underlying these relations are warranted.</p>
              </sec>
            </sec>
            <sec id="jah37426-sec-0026">
              <title>Sources of Funding</title>
              <p>The SPIRIT study was funded by the Maryland Cigarette Restitution Fund. N.T.M. was supported by the National Heart, Lung, and Blood Institute of the (K01HL141589). H.C.Y. was supported in part by the National Cancer Institute’s Cancer Centers Support Grant to the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5P30CA006973). C.T. was supported by the National Heart, Lung, and Blood Institute grant T32HL007024.</p>
            </sec>
            <sec id="jah37426-sec-0027">
              <title>Disclosures</title>
              <p>None.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="jah37426-sup-0001" position="float" content-type="local-data">
                <caption>
                  <p>Tables S1–S6</p>
                  <p>Figures S1–S4</p>
                </caption>
                <media xlink:href="JAH3-11-e024763-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="jah37426-sec-0025">
              <title>Acknowledgments</title>
              <p>Designed research: H.C.Y., N.T.M.; Conducted research: H.C.Y., L.J.A., N.T.M.; Performed statistical analysis: C.T., N.T.M.; Wrote paper: C.T., N.T.M.; Other – Data interpretation and manuscript revision: C.T., E.R.M., H.C.Y., K.W., L.J.A., N.M., N.T.M., S.P.J.</p>
            </ack>
            <ref-list content-type="cited-references" id="jah37426-bibl-0001">
              <title>References</title>
              <ref id="jah37426-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0001"><string-name><surname>Kim</surname><given-names>S</given-names></string-name>, <string-name><surname>Goel</surname><given-names>R</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>A</given-names></string-name>, <string-name><surname>Qi</surname><given-names>Y</given-names></string-name>, <string-name><surname>Lobaton</surname><given-names>G</given-names></string-name>, <string-name><surname>Hosaka</surname><given-names>K</given-names></string-name>, <string-name><surname>Mohammed</surname><given-names>M</given-names></string-name>, <string-name><surname>Handberg</surname><given-names>E</given-names></string-name>, <string-name><surname>Richards</surname><given-names>E</given-names></string-name>, <string-name><surname>Pepine</surname><given-names>C</given-names></string-name>, et al. <article-title>Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure</article-title>. <source>Clin Sci (Lond)</source>. <year>2018</year>;<volume>132</volume>:<fpage>701</fpage>–<lpage>718</lpage>. doi: <pub-id pub-id-type="doi">10.1042/CS20180087</pub-id>
<pub-id pub-id-type="pmid">29507058</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0002"><string-name><surname>Onyszkiewicz</surname><given-names>M</given-names></string-name>, <string-name><surname>Gawrys‐Kopczynska</surname><given-names>M</given-names></string-name>, <string-name><surname>Konopelski</surname><given-names>P</given-names></string-name>, <string-name><surname>Aleksandrowicz</surname><given-names>M</given-names></string-name>, <string-name><surname>Sawicka</surname><given-names>A</given-names></string-name>, <string-name><surname>Koźniewska</surname><given-names>E</given-names></string-name>, <string-name><surname>Samborowska</surname><given-names>E</given-names></string-name>, <string-name><surname>Ufnal</surname><given-names>M</given-names></string-name>. <article-title>Butyric acid, a gut bacteria metabolite, lowers arterial blood pressure via colon‐vagus nerve signaling and GPR41/43 receptors</article-title>. <source>Pflügers Archiv ‐ Eur J Physiol</source>. <year>2019</year>;<volume>471</volume>:<fpage>1441</fpage>–<lpage>1453</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00424-019-02322-y</pub-id>
<pub-id pub-id-type="pmid">31728701</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0003"><string-name><surname>Yang</surname><given-names>T</given-names></string-name>, <string-name><surname>Magee</surname><given-names>KL</given-names></string-name>, <string-name><surname>Colon‐Perez</surname><given-names>LM</given-names></string-name>, <string-name><surname>Larkin</surname><given-names>R</given-names></string-name>, <string-name><surname>Liao</surname><given-names>Y‐S</given-names></string-name>, <string-name><surname>Balazic</surname><given-names>E</given-names></string-name>, <string-name><surname>Cowart</surname><given-names>JR</given-names></string-name>, <string-name><surname>Arocha</surname><given-names>R</given-names></string-name>, <string-name><surname>Redler</surname><given-names>TY</given-names></string-name>, <string-name><surname>Febo</surname><given-names>M</given-names></string-name>, et al. <article-title>Impaired butyrate absorption in the proximal colon, low serum butyrate and diminished central effects of butyrate on blood pressure in spontaneously hypertensive rats</article-title>. <source>Acta Physiol (Oxf)</source>. <year>2019</year>;<volume>226</volume>:<elocation-id>e13256</elocation-id>. doi: <pub-id pub-id-type="doi">10.1111/apha.13256</pub-id><pub-id pub-id-type="pmid">30656835</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0004"><string-name><surname>Pluznick</surname><given-names>JL</given-names></string-name>. <article-title>Microbial short‐chain fatty acids and blood pressure regulation</article-title>. <source>Curr Hypertens Rep</source>. <year>2017</year>;<volume>19</volume>:<fpage>25</fpage>. doi: <pub-id pub-id-type="doi">10.1007/s11906-017-0722-5</pub-id><pub-id pub-id-type="pmid">28315048</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0005"><string-name><surname>Poll</surname><given-names>BG</given-names></string-name>, <string-name><surname>Cheema</surname><given-names>MU</given-names></string-name>, <string-name><surname>Pluznick</surname><given-names>JL</given-names></string-name>. <article-title>Gut microbial metabolites and blood pressure regulation: focus on SCFAs and TMAO</article-title>. <source>Physiology (Bethesda, Md)</source>. <year>2020</year>;<volume>35</volume>:<fpage>275</fpage>–<lpage>284</lpage>. doi: <pub-id pub-id-type="doi">10.1152/physiol.00004.2020</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah37426-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0006"><string-name><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name><surname>He</surname><given-names>T</given-names></string-name>, <string-name><surname>Becker</surname><given-names>S</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>G</given-names></string-name>, <string-name><surname>Li</surname><given-names>D</given-names></string-name>, <string-name><surname>Ma</surname><given-names>X</given-names></string-name>. <article-title>Butyrate: a double‐edged sword for health?</article-title><source>Adv Nutr</source>. <year>2018</year>;<volume>9</volume>:<fpage>21</fpage>–<lpage>29</lpage>. doi: <pub-id pub-id-type="doi">10.1093/advances/nmx009</pub-id>
<pub-id pub-id-type="pmid">29438462</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0007"><string-name><surname>de la Cuesta‐Zuluaga</surname><given-names>J</given-names></string-name>, <string-name><surname>Mueller</surname><given-names>NT</given-names></string-name>, <string-name><surname>Alvarez‐Quintero</surname><given-names>R</given-names></string-name>, <string-name><surname>Velasquez‐Mejia</surname><given-names>EP</given-names></string-name>, <string-name><surname>Sierra</surname><given-names>JA</given-names></string-name>, <string-name><surname>Corrales‐Agudelo</surname><given-names>V</given-names></string-name>, <string-name><surname>Carmona</surname><given-names>JA</given-names></string-name>, <string-name><surname>Abad</surname><given-names>JM</given-names></string-name>, <string-name><surname>Escobar</surname><given-names>JS</given-names></string-name>. <article-title>Higher fecal short‐chain fatty acid levels are associated with gut microbiome dysbiosis, obesity, hypertension and cardiometabolic disease risk factors</article-title>. <source>Nutrients</source>. <year>2018</year>;<volume>11</volume>:<fpage>51</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu11010051</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0008"><string-name><surname>Calderón‐Pérez</surname><given-names>L</given-names></string-name>, <string-name><surname>Gosalbes</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Yuste</surname><given-names>S</given-names></string-name>, <string-name><surname>Valls</surname><given-names>RM</given-names></string-name>, <string-name><surname>Pedret</surname><given-names>A</given-names></string-name>, <string-name><surname>Llauradó</surname><given-names>E</given-names></string-name>, <string-name><surname>Jimenez‐Hernandez</surname><given-names>N</given-names></string-name>, <string-name><surname>Artacho</surname><given-names>A</given-names></string-name>, <string-name><surname>Pla‐Pagà</surname><given-names>L</given-names></string-name>, <string-name><surname>Companys</surname><given-names>J</given-names></string-name>, et al. <article-title>Gut metagenomic and short chain fatty acids signature in hypertension: a cross‐sectional study</article-title>. <source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>:<fpage>6436</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-020-63475-w</pub-id><pub-id pub-id-type="pmid">32296109</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0009"><string-name><surname>Mueller</surname><given-names>NT</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>M</given-names></string-name>, <string-name><surname>Juraschek</surname><given-names>SP</given-names></string-name>, <string-name><surname>Miller</surname><given-names>ER</given-names></string-name>, <string-name><surname>Appel</surname><given-names>LJ</given-names></string-name>. <article-title>Effects of high‐fiber diets enriched with carbohydrate, protein, or unsaturated fat on circulating short chain fatty acids: results from the OmniHeart randomized trial</article-title>. <source>Am J Clin Nutr</source>. <year>2020</year>;<volume>111</volume>:<fpage>545</fpage>–<lpage>554</lpage>. doi: <pub-id pub-id-type="doi">10.1093/ajcn/nqz322</pub-id>
<pub-id pub-id-type="pmid">31927581</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0010"><string-name><surname>Huart</surname><given-names>J</given-names></string-name>, <string-name><surname>Leenders</surname><given-names>J</given-names></string-name>, <string-name><surname>Taminiau</surname><given-names>B</given-names></string-name>, <string-name><surname>Descy</surname><given-names>J</given-names></string-name>, <string-name><surname>Saint‐Remy</surname><given-names>A</given-names></string-name>, <string-name><surname>Daube</surname><given-names>G</given-names></string-name>, <string-name><surname>Krzesinski</surname><given-names>JM</given-names></string-name>, <string-name><surname>Melin</surname><given-names>P</given-names></string-name>, <string-name><surname>de Tullio</surname><given-names>P</given-names></string-name>, <string-name><surname>Jouret</surname><given-names>F</given-names></string-name>. <article-title>Gut microbiota and fecal levels of short‐chain fatty acids differ upon 24‐hour blood pressure levels in men</article-title>. <source>Hypertension</source>. <year>2019</year>;<volume>74</volume>:<fpage>1005</fpage>–<lpage>1013</lpage>. doi: <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.118.12588</pub-id>
<pub-id pub-id-type="pmid">31352822</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0011"><string-name><surname>Chang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Q</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name><surname>Di</surname><given-names>W</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>. <article-title>Short‐chain fatty acids accompanying changes in the gut microbiome contribute to the development of hypertension in patients with preeclampsia</article-title>. <source>Clin Sci (Lond)</source>. <year>2020</year>;<volume>134</volume>:<fpage>289</fpage>–<lpage>302</lpage>. doi: <pub-id pub-id-type="doi">10.1042/cs20191253</pub-id>
<pub-id pub-id-type="pmid">31961431</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0012"><string-name><surname>Verhaar</surname><given-names>BJH</given-names></string-name>, <string-name><surname>Collard</surname><given-names>D</given-names></string-name>, <string-name><surname>Prodan</surname><given-names>A</given-names></string-name>, <string-name><surname>Levels</surname><given-names>JHM</given-names></string-name>, <string-name><surname>Zwinderman</surname><given-names>AH</given-names></string-name>, <string-name><surname>Bäckhed</surname><given-names>F</given-names></string-name>, <string-name><surname>Vogt</surname><given-names>L</given-names></string-name>, <string-name><surname>Peters</surname><given-names>MJL</given-names></string-name>, <string-name><surname>Muller</surname><given-names>M</given-names></string-name>, <string-name><surname>Nieuwdorp</surname><given-names>M</given-names></string-name>, et al. <article-title>Associations between gut microbiota, faecal short‐chain fatty acids, and blood pressure across ethnic groups: the HELIUS study</article-title>. <source>Eur Heart J</source>. <year>2020</year>;<volume>41</volume>:<fpage>4259</fpage>–<lpage>4267</lpage>. doi: <pub-id pub-id-type="doi">10.1093/eurheartj/ehaa704</pub-id>
<pub-id pub-id-type="pmid">32869053</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0013"><string-name><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name><surname>He</surname><given-names>FJ</given-names></string-name>, <string-name><surname>Dong</surname><given-names>Y</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name><surname>Harshfield</surname><given-names>GA</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>H</given-names></string-name>. <article-title>Modest sodium reduction increases circulating short‐chain fatty acids in untreated hypertensives: a randomized, double‐blind. Placebo‐controlled trial</article-title>. <source>Hypertension</source>. <year>2020</year>;<volume>76</volume>:<fpage>73</fpage>–<lpage>79</lpage>. doi: <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.120.14800</pub-id>
<pub-id pub-id-type="pmid">32475312</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0014"><string-name><surname>Vijay</surname><given-names>A</given-names></string-name>, <string-name><surname>Astbury</surname><given-names>S</given-names></string-name>, <string-name><surname>Panayiotis</surname><given-names>L</given-names></string-name>, <string-name><surname>Marques</surname><given-names>FZ</given-names></string-name>, <string-name><surname>Spector</surname><given-names>TD</given-names></string-name>, <string-name><surname>Menni</surname><given-names>C</given-names></string-name>, <string-name><surname>Valdes</surname><given-names>AM</given-names></string-name>. <article-title>Dietary interventions reduce traditional and novel cardiovascular risk markers by altering the gut microbiome and their metabolites</article-title>. <source>Front Cardiovasc Med</source>. <year>2021</year>;<volume>8</volume>. doi: <pub-id pub-id-type="doi">10.3389/fcvm.2021.691564</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0015"><string-name><surname>Müller</surname><given-names>M</given-names></string-name>, <string-name><surname>Hernández</surname><given-names>MAG</given-names></string-name>, <string-name><surname>Goossens</surname><given-names>GH</given-names></string-name>, <string-name><surname>Reijnders</surname><given-names>D</given-names></string-name>, <string-name><surname>Holst</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Jocken</surname><given-names>JWE</given-names></string-name>, <string-name><surname>van Eijk</surname><given-names>H</given-names></string-name>, <string-name><surname>Canfora</surname><given-names>EE</given-names></string-name>, <string-name><surname>Blaak</surname><given-names>EE</given-names></string-name>. <article-title>Circulating but not faecal short‐chain fatty acids are related to insulin sensitivity, lipolysis and GLP‐1 concentrations in humans</article-title>. <source>Sci Rep</source>. <year>2019</year>;<volume>9</volume>:<fpage>12515</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-019-48775-0</pub-id><pub-id pub-id-type="pmid">31467327</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0016"><string-name><surname>Yeh</surname><given-names>HC</given-names></string-name>, <string-name><surname>Maruthur</surname><given-names>NM</given-names></string-name>, <string-name><surname>Wang</surname><given-names>NY</given-names></string-name>, <string-name><surname>Jerome</surname><given-names>GJ</given-names></string-name>, <string-name><surname>Dalcin</surname><given-names>AT</given-names></string-name>, <string-name><surname>Tseng</surname><given-names>E</given-names></string-name>, <string-name><surname>White</surname><given-names>K</given-names></string-name>, <string-name><surname>Miller</surname><given-names>ER</given-names></string-name>, <string-name><surname>Juraschek</surname><given-names>SP</given-names></string-name>, <string-name><surname>Mueller</surname><given-names>NT</given-names></string-name>, et al. <article-title>Effects of behavioral weight loss and metformin on insulin‐like growth factors in cancer survivors: a randomized trial</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2021</year>;<volume>106</volume>:<fpage>e4179</fpage>–<lpage>e4191</lpage>. doi: <pub-id pub-id-type="doi">10.1210/clinem/dgab266</pub-id>
<pub-id pub-id-type="pmid">33884414</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0017"><string-name><surname>Zhao</surname><given-names>G</given-names></string-name>, <string-name><surname>Nyman</surname><given-names>M</given-names></string-name>, <string-name><surname>Jönsson</surname><given-names>JA</given-names></string-name>. <article-title>Rapid determination of short‐chain fatty acids in colonic contents and faeces of humans and rats by acidified water‐extraction and direct‐injection gas chromatography</article-title>. <source>Biomed Chromatogr: BMC</source>. <year>2006</year>;<volume>20</volume>:<fpage>674</fpage>–<lpage>682</lpage>. doi: <pub-id pub-id-type="doi">10.1002/bmc.580</pub-id>
<pub-id pub-id-type="pmid">16206138</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0018"><string-name><surname>Mueller</surname><given-names>NT</given-names></string-name>, <string-name><surname>Differding</surname><given-names>MK</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>M</given-names></string-name>, <string-name><surname>Maruthur</surname><given-names>NM</given-names></string-name>, <string-name><surname>Juraschek</surname><given-names>SP</given-names></string-name>, <string-name><surname>Miller</surname><given-names>ER</given-names><suffix>III</suffix></string-name>, <string-name><surname>Appel</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Yeh</surname><given-names>HC</given-names></string-name>. <article-title>Metformin affects gut microbiome composition and function and circulating short‐chain fatty acids: a randomized trial</article-title>. <source>Diabetes Care</source>. <year>2021</year>;<volume>44</volume>:<fpage>1462</fpage>–<lpage>1471</lpage>. doi: <pub-id pub-id-type="doi">10.2337/dc20-2257</pub-id>
<pub-id pub-id-type="pmid">34006565</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0019"><string-name><surname>Whelton</surname><given-names>PK</given-names></string-name>, <string-name><surname>Carey</surname><given-names>RM</given-names></string-name>, <string-name><surname>Aronow</surname><given-names>WS</given-names></string-name>, <string-name><surname>Casey</surname><given-names>DE</given-names></string-name>, <string-name><surname>Collins</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Dennison Himmelfarb</surname><given-names>C</given-names></string-name>, <string-name><surname>DePalma</surname><given-names>SM</given-names></string-name>, <string-name><surname>Gidding</surname><given-names>S</given-names></string-name>, <string-name><surname>Jamerson</surname><given-names>KA</given-names></string-name>, <string-name><surname>Jones</surname><given-names>DW</given-names></string-name>, et al. <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</article-title>. <source>Hypertension</source>. <year>2018</year>;<volume>71</volume>:<fpage>e13</fpage>–<lpage>e115</lpage>. doi: <pub-id pub-id-type="doi">10.1161/hyp.0000000000000065</pub-id>
<pub-id pub-id-type="pmid">29133356</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0020"><string-name><surname>Bobb</surname><given-names>JF</given-names></string-name>, <string-name><surname>Valeri</surname><given-names>L</given-names></string-name>, <string-name><surname>Claus Henn</surname><given-names>B</given-names></string-name>, <string-name><surname>Christiani</surname><given-names>DC</given-names></string-name>, <string-name><surname>Wright</surname><given-names>RO</given-names></string-name>, <string-name><surname>Mazumdar</surname><given-names>M</given-names></string-name>, <string-name><surname>Godleski</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Coull</surname><given-names>BA</given-names></string-name>. <article-title>Bayesian kernel machine regression for estimating the health effects of multi‐pollutant mixtures</article-title>. <source>Biostatistics (Oxford, England)</source>. <year>2015</year>;<volume>16</volume>:<fpage>493</fpage>–<lpage>508</lpage>. doi: <pub-id pub-id-type="doi">10.1093/biostatistics/kxu058</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah37426-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0021"><string-name><surname>Buckley</surname><given-names>JP</given-names></string-name>, <string-name><surname>Doherty</surname><given-names>BT</given-names></string-name>, <string-name><surname>Keil</surname><given-names>AP</given-names></string-name>, <string-name><surname>Engel</surname><given-names>SM</given-names></string-name>. <article-title>Statistical approaches for estimating sex‐specific effects in endocrine disruptors research</article-title>. <source>Environ Health Perspect</source>. <year>2017</year>;<volume>125</volume>:067013. doi: <pub-id pub-id-type="doi">10.1289/EHP334</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0022"><string-name><surname>Bobb</surname><given-names>JF</given-names></string-name>, <string-name><surname>Claus Henn</surname><given-names>B</given-names></string-name>, <string-name><surname>Valeri</surname><given-names>L</given-names></string-name>, <string-name><surname>Coull</surname><given-names>BA</given-names></string-name>. <article-title>Statistical software for analyzing the health effects of multiple concurrent exposures via Bayesian kernel machine regression</article-title>. <source>Environ Health</source>. <year>2018</year>;<volume>17</volume>:<fpage>67</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12940-018-0413-y</pub-id><pub-id pub-id-type="pmid">30126431</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="miscellaneous" id="jah37426-cit-0023"><string-name><surname>Harrell</surname><given-names>FE</given-names><suffix>Jr</suffix></string-name>. <collab collab-type="authors">rms: Regression Modeling Strategies</collab>
. <year>2021</year>.</mixed-citation>
              </ref>
              <ref id="jah37426-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0024"><string-name><surname>Rahat‐Rozenbloom</surname><given-names>S</given-names></string-name>, <string-name><surname>Fernandes</surname><given-names>J</given-names></string-name>, <string-name><surname>Gloor</surname><given-names>GB</given-names></string-name>, <string-name><surname>Wolever</surname><given-names>TM</given-names></string-name>. <article-title>Evidence for greater production of colonic short‐chain fatty acids in overweight than lean humans</article-title>. <source>Int J Obes (2002)</source>. <year>2014</year>;<volume>38</volume>:<fpage>1525</fpage>–<lpage>1531</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ijo.2014.46</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah37426-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0025"><string-name><surname>Schwiertz</surname><given-names>A</given-names></string-name>, <string-name><surname>Taras</surname><given-names>D</given-names></string-name>, <string-name><surname>Schäfer</surname><given-names>K</given-names></string-name>, <string-name><surname>Beijer</surname><given-names>S</given-names></string-name>, <string-name><surname>Bos</surname><given-names>NA</given-names></string-name>, <string-name><surname>Donus</surname><given-names>C</given-names></string-name>, <string-name><surname>Hardt</surname><given-names>PD</given-names></string-name>. <article-title>Microbiota and SCFA in lean and overweight healthy subjects</article-title>. <source>Obesity</source>. <year>2010</year>;<volume>18</volume>:<fpage>190</fpage>–<lpage>195</lpage>. doi: <pub-id pub-id-type="doi">10.1038/oby.2009.167</pub-id>
<pub-id pub-id-type="pmid">19498350</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0026"><string-name><surname>Turnbaugh</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Ley</surname><given-names>RE</given-names></string-name>, <string-name><surname>Mahowald</surname><given-names>MA</given-names></string-name>, <string-name><surname>Magrini</surname><given-names>V</given-names></string-name>, <string-name><surname>Mardis</surname><given-names>ER</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>JI</given-names></string-name>. <article-title>An obesity‐associated gut microbiome with increased capacity for energy harvest</article-title>. <source>Nature</source>. <year>2006</year>;<volume>444</volume>:<fpage>1027</fpage>–<lpage>1031</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature05414</pub-id>
<pub-id pub-id-type="pmid">17183312</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0027"><string-name><surname>Lin</surname><given-names>HV</given-names></string-name>, <string-name><surname>Frassetto</surname><given-names>A</given-names></string-name>, <string-name><surname>Kowalik Jr</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Nawrocki</surname><given-names>AR</given-names></string-name>, <string-name><surname>Lu</surname><given-names>MM</given-names></string-name>, <string-name><surname>Kosinski</surname><given-names>JR</given-names></string-name>, <string-name><surname>Hubert</surname><given-names>JA</given-names></string-name>, <string-name><surname>Szeto</surname><given-names>D</given-names></string-name>, <string-name><surname>Yao</surname><given-names>X</given-names></string-name>, <string-name><surname>Forrest</surname><given-names>G</given-names></string-name>, et al. <article-title>Butyrate and propionate protect against diet‐induced obesity and regulate gut hormones via free fatty acid receptor 3‐independent mechanisms</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>:<elocation-id>e35240</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0035240</pub-id><pub-id pub-id-type="pmid">22506074</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0028"><string-name><surname>Lu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Fan</surname><given-names>C</given-names></string-name>, <string-name><surname>Li</surname><given-names>P</given-names></string-name>, <string-name><surname>Lu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Chang</surname><given-names>X</given-names></string-name>, <string-name><surname>Qi</surname><given-names>K</given-names></string-name>. <article-title>Short chain fatty acids prevent high‐fat‐diet‐induced obesity in mice by regulating G protein‐coupled receptors and gut microbiota</article-title>. <source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>:<fpage>37589</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep37589</pub-id><pub-id pub-id-type="pmid">27892486</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0029"><string-name><surname>Chambers</surname><given-names>ES</given-names></string-name>, <string-name><surname>Viardot</surname><given-names>A</given-names></string-name>, <string-name><surname>Psichas</surname><given-names>A</given-names></string-name>, <string-name><surname>Morrison</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Murphy</surname><given-names>KG</given-names></string-name>, <string-name><surname>Zac‐Varghese</surname><given-names>SEK</given-names></string-name>, <string-name><surname>MacDougall</surname><given-names>K</given-names></string-name>, <string-name><surname>Preston</surname><given-names>T</given-names></string-name>, <string-name><surname>Tedford</surname><given-names>C</given-names></string-name>, <string-name><surname>Finlayson</surname><given-names>GS</given-names></string-name>, et al. <article-title>Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults</article-title>. <source>Gut</source>. <year>2015</year>;<volume>64</volume>:<fpage>1744</fpage>. doi: <pub-id pub-id-type="doi">10.1136/gutjnl-2014-307913</pub-id><pub-id pub-id-type="pmid">25500202</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0030"><string-name><surname>Robles‐Vera</surname><given-names>I</given-names></string-name>, <string-name><surname>Toral</surname><given-names>M</given-names></string-name>, <string-name><surname>la Visitación</surname><given-names>N</given-names></string-name>, <string-name><surname>Sánchez</surname><given-names>M</given-names></string-name>, <string-name><surname>Gómez‐Guzmán</surname><given-names>M</given-names></string-name>, <string-name><surname>Romero</surname><given-names>M</given-names></string-name>, <string-name><surname>Yang</surname><given-names>T</given-names></string-name>, <string-name><surname>Izquierdo‐Garcia</surname><given-names>JL</given-names></string-name>, <string-name><surname>Jiménez</surname><given-names>R</given-names></string-name>, <string-name><surname>Ruiz‐Cabello</surname><given-names>J</given-names></string-name>, et al. <article-title>Probiotics prevent dysbiosis and the rise in blood pressure in genetic hypertension: role of short‐chain fatty acids</article-title>. <source>Mol Nutr Food Res</source>. <year>2020</year>;<volume>64</volume>:<elocation-id>e1900616</elocation-id>. doi: <pub-id pub-id-type="doi">10.1002/mnfr.201900616</pub-id><pub-id pub-id-type="pmid">31953983</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0031"><string-name><surname>Kaye</surname><given-names>DM</given-names></string-name>, <string-name><surname>Shihata</surname><given-names>WA</given-names></string-name>, <string-name><surname>Jama</surname><given-names>HA</given-names></string-name>, <string-name><surname>Tsyganov</surname><given-names>K</given-names></string-name>, <string-name><surname>Ziemann</surname><given-names>M</given-names></string-name>, <string-name><surname>Kiriazis</surname><given-names>H</given-names></string-name>, <string-name><surname>Horlock</surname><given-names>D</given-names></string-name>, <string-name><surname>Vijay</surname><given-names>A</given-names></string-name>, <string-name><surname>Giam</surname><given-names>B</given-names></string-name>, <string-name><surname>Vinh</surname><given-names>A</given-names></string-name>, et al. <article-title>Deficiency of prebiotic fiber and insufficient signaling through gut metabolite‐sensing receptors leads to cardiovascular disease</article-title>. <source>Circulation</source>. <year>2020</year>;<volume>141</volume>:<fpage>1393</fpage>–<lpage>1403</lpage>. doi: <pub-id pub-id-type="doi">10.1161/circulationaha.119.043081</pub-id>
<pub-id pub-id-type="pmid">32093510</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0032"><string-name><surname>Parada Venegas</surname><given-names>D</given-names></string-name>, <string-name><surname>De la Fuente</surname><given-names>MK</given-names></string-name>, <string-name><surname>Landskron</surname><given-names>G</given-names></string-name>, <string-name><surname>González</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Quera</surname><given-names>R</given-names></string-name>, <string-name><surname>Dijkstra</surname><given-names>G</given-names></string-name>, <string-name><surname>Harmsen</surname><given-names>HJM</given-names></string-name>, <string-name><surname>Faber</surname><given-names>KN</given-names></string-name>, <string-name><surname>Hermoso</surname><given-names>MA</given-names></string-name>. <article-title>Short chain fatty acids (SCFAs)‐mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases</article-title>. <source>Front Immunol</source>. <year>2019</year>;<volume>10</volume>:<fpage>277</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2019.00277</pub-id><pub-id pub-id-type="pmid">30915065</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0033"><string-name><surname>Markle</surname><given-names>JG</given-names></string-name>, <string-name><surname>Frank</surname><given-names>DN</given-names></string-name>, <string-name><surname>Mortin‐Toth</surname><given-names>S</given-names></string-name>, <string-name><surname>Robertson</surname><given-names>CE</given-names></string-name>, <string-name><surname>Feazel</surname><given-names>LM</given-names></string-name>, <string-name><surname>Rolle‐Kampczyk</surname><given-names>U</given-names></string-name>, <string-name><surname>von Bergen</surname><given-names>M</given-names></string-name>, <string-name><surname>McCoy</surname><given-names>KD</given-names></string-name>, <string-name><surname>Macpherson</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Danska</surname><given-names>JS</given-names></string-name>. <article-title>Sex differences in the gut microbiome drive hormone‐dependent regulation of autoimmunity</article-title>. <source>Science</source>. <year>2013</year>;<volume>339</volume>:<fpage>1084</fpage>–<lpage>1088</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.1233521</pub-id>
<pub-id pub-id-type="pmid">23328391</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0034"><string-name><surname>Wallis</surname><given-names>A</given-names></string-name>, <string-name><surname>Butt</surname><given-names>H</given-names></string-name>, <string-name><surname>Ball</surname><given-names>M</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>DP</given-names></string-name>, <string-name><surname>Bruck</surname><given-names>D</given-names></string-name>. <article-title>Support for the microgenderome: associations in a human clinical population</article-title>. <source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>:<fpage>19171</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep19171</pub-id><pub-id pub-id-type="pmid">26757840</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0035"><string-name><surname>Gillis</surname><given-names>EE</given-names></string-name>, <string-name><surname>Sullivan</surname><given-names>JC</given-names></string-name>. <article-title>Sex differences in hypertension: recent advances</article-title>. <source>Hypertension</source>. <year>2016</year>;<volume>68</volume>:<fpage>1322</fpage>–<lpage>1327</lpage>. doi: <pub-id pub-id-type="doi">10.1161/hypertensionaha.116.06602</pub-id>
<pub-id pub-id-type="pmid">27777357</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0036"><string-name><surname>Regitz‐Zagrosek</surname><given-names>V</given-names></string-name>, <string-name><surname>Kararigas</surname><given-names>G</given-names></string-name>. <article-title>Mechanistic pathways of sex differences in cardiovascular disease</article-title>. <source>Physiol Rev</source>. <year>2017</year>;<volume>97</volume>:<fpage>1</fpage>–<lpage>37</lpage>. doi: <pub-id pub-id-type="doi">10.1152/physrev.00021.2015</pub-id>
<pub-id pub-id-type="pmid">27807199</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0037"><string-name><surname>Bolnick</surname><given-names>DI</given-names></string-name>, <string-name><surname>Snowberg</surname><given-names>LK</given-names></string-name>, <string-name><surname>Hirsch</surname><given-names>PE</given-names></string-name>, <string-name><surname>Lauber</surname><given-names>CL</given-names></string-name>, <string-name><surname>Org</surname><given-names>E</given-names></string-name>, <string-name><surname>Parks</surname><given-names>B</given-names></string-name>, <string-name><surname>Lusis</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Knight</surname><given-names>R</given-names></string-name>, <string-name><surname>Caporaso</surname><given-names>JG</given-names></string-name>, <string-name><surname>Svanbäck</surname><given-names>R</given-names></string-name>. <article-title>Individual diet has sex‐dependent effects on vertebrate gut microbiota</article-title>. <source>Nat Commun</source>. <year>2014</year>;<volume>5</volume>:<fpage>4500</fpage>. doi: <pub-id pub-id-type="doi">10.1038/ncomms5500</pub-id><pub-id pub-id-type="pmid">25072318</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0038"><string-name><surname>Klein</surname><given-names>SL</given-names></string-name>, <string-name><surname>Flanagan</surname><given-names>KL</given-names></string-name>. <article-title>Sex differences in immune responses</article-title>. <source>Nat Rev Immunol</source>. <year>2016</year>;<volume>16</volume>:<fpage>626</fpage>–<lpage>638</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nri.2016.90</pub-id>
<pub-id pub-id-type="pmid">27546235</pub-id></mixed-citation>
              </ref>
              <ref id="jah37426-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="jah37426-cit-0039"><string-name><surname>Wilck</surname><given-names>N</given-names></string-name>, <string-name><surname>Matus</surname><given-names>MG</given-names></string-name>, <string-name><surname>Kearney</surname><given-names>SM</given-names></string-name>, <string-name><surname>Olesen</surname><given-names>SW</given-names></string-name>, <string-name><surname>Forslund</surname><given-names>K</given-names></string-name>, <string-name><surname>Bartolomaeus</surname><given-names>H</given-names></string-name>, <string-name><surname>Haase</surname><given-names>S</given-names></string-name>, <string-name><surname>Mähler</surname><given-names>A</given-names></string-name>, <string-name><surname>Balogh</surname><given-names>A</given-names></string-name>, <string-name><surname>Markó</surname><given-names>L</given-names></string-name>, et al. <article-title>Salt‐responsive gut commensal modulates TH17 axis and disease</article-title>. <source>Nature</source>. <year>2017</year>;<volume>551</volume>:<fpage>585</fpage>–<lpage>589</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature24628</pub-id>
<pub-id pub-id-type="pmid">29143823</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
